Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, TRI, FVT

Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference


Professor Jacky Smith will present on the reduction of cough bouts with nalbuphine ER observed in patients with IPF in the CANAL trial

NEW HAVEN, Conn., April 9, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduviotm (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2 CANAL trial will be presented at the American Thoracic Society (ATS) 2024 International Conference being held in San Diego, CA, from May 17-22. The presentation will take place on May 19th.

Trevi CANAL trial data being presented on May 19 at American Thoracic Society Conference

ATS 2024 International Conference
May 17-22, 2024, San Diego, CA
Session: A104: Advances in the Diagnosis and Treatment of ILD
Abstract: Nalbuphine Extended-release Reduces Cough Bouts in Patients With Idiopathic Pulmonary Fibrosis
Presentation: May 19, 3:00 p.m. - 4:15 p.m. PT
Location: San Diego Convention Center, Room 33A-C (Upper Level)
Presenter: Jacky Smith, MB, ChB, FRCP, PhD, Professor of Respiratory Medicine at the University of Manchester, and an Honorary Consultant at Manchester University NHS Foundation Trust. Director of the NIHR Manchester Clinical Research Facility, Respiratory Theme Lead in the NIHR Manchester Biomedical Research Centre and an NIHR Senior Investigator.

Registration details: https://conference.thoracic.org/

About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduviotm (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Trevi is also developing Haduvio for prurigo nodularis. Haduvio is a dual ?-opioid receptor agonist and µ-opioid receptor antagonist that works both centrally in the brain as well as peripherally in the lungs and has the potential for a synergistic antitussive effect to treat chronic cough.

The impact of chronic cough is significant and often leads to a decline in patients' social, physical, and psychological quality of life. In IPF, chronic cough may lead to worsening disease and may be associated with a higher risk of progression, death, or need for lung transplant. There are no approved therapies for the treatment of chronic cough in IPF and current treatment options provide minimal relief to patients. RCC affects up to 10% of the adult population, and Haduvio's expansion into RCC has the potential to reach patients suffering from moderate to severe chronic cough. There are also no approved therapies for RCC in the US.

Parenteral nalbuphine is not scheduled by the U.S. Drug Enforcement Agency. Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.

For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.

Investor Contact
Katie McManus
Trevi Therapeutics, Inc.
203-304-2499
[email protected] 

Media Contact
Rosalia Scampoli
914-815-1465
[email protected] 

 

SOURCE Trevi Therapeutics, Inc.


These press releases may also interest you

at 14:15
WHOOP Announces Significant Global Expansion, Appoints New Senior Leadership
WHOOP, the human performance company, today announced the expansion of its global footprint, now shipping to 56 markets worldwide, with more launches ahead. Additionally, the WHOOP app is now available in Italian and Spanish (Latin America), as well...

at 14:06
Biden-Harris Administration Announces New Investment in Innovative Technologies to Improve Efficiency of Federal Permitting for Critical Infrastructure
Today, the Permitting Council (Federal Permitting Improvement Steering Council) is pleased to announce the allocation of over $30 million in funding to enhance permitting efficiency across the federal government as part of President Biden's Investing...

at 14:00
Network-powered Innovation comes to Venture Capital: Dickson & Main Fund I Launched to Support the University of Arkansas System and Early-Stage Tech Founders--Innovative Structure will help sustain University innovation efforts for years to come
FortySix Venture Capital LLC (46VC), a venture capital management firm with offices in Bentonville, AR and Tulsa, OK, is proud to announce the launch of Dickson & Main Fund I. The fund is managed by a team of experienced investors at 46VC and will...

at 14:00
Humanoid Robots Move Gracefully with CCTY Technology
To help robot makers develop humanoid robots that emulate the mobility and flexibility of human limbs, CCTY designs and manufactures bespoke parts tailored to the unique requirements of each project. During The Robotics Summit, held in Boston on May...

at 13:50
HONEYWELL ANNOUNCES QUARTERLY DIVIDEND
Honeywell today announced that its Board of Directors has declared a quarterly dividend payment of $1.08 per share on the Company's common stock. The dividend is payable on June 7, 2024, out of surplus to holders of record at the close of business...

at 13:39
FDA to Hold Listening Session as Part of Broader Work to Optimize Use of, and Processes for, Advisory Committees
Today, the U.S. Food and Drug Administration announced it will host a listening session in June as part of its broader work to optimize the use of, and processes for, advisory committees. This virtual public meeting will focus on the composition of...

More news about Science and technology...


News published on and distributed by: